Mahmood A, FitzGerald A J, Marchbank T, Ntatsaki E, Murray D, Ghosh S, Playford R J
Department of Gastroenterology, Imperial College London, UK.
Gut. 2007 Feb;56(2):168-75. doi: 10.1136/gut.2006.099929. Epub 2006 Jun 15.
Zinc carnosine (ZnC) is a health food product claimed to possess health-promoting and gastrointestinal supportive activity. Scientific evidence underlying these claims is, however, limited.
To examine the effect of ZnC on various models of gut injury and repair, and in a clinical trial.
In vitro studies used pro-migratory (wounded monolayer) and proliferation ([(3)H]-thymidine incorporation) assays of human colonic (HT29), rat intestinal epithelial (RIE) and canine kidney (MDCK) epithelial cells. In vivo studies used a rat model of gastric damage (indomethacin/restraint) and a mouse model of small-intestinal (indomethacin) damage. Healthy volunteers (n = 10) undertook a randomised crossover trial comparing changes in gut permeability (lactulose:rhamnose ratios) before and after 5 days of indomethacin treatment (50 mg three times a day) with ZnC (37.5 mg twice daily) or placebo coadministration.
ZnC stimulated migration and proliferation of cells in a dose-dependent manner (maximum effects in both assays at 100 micromol/l using HT29 cells), causing an approximate threefold increase in migration and proliferation (both p<0.01). Oral ZnC decreased gastric (75% reduction at 5 mg/ml) and small-intestinal injury (50% reduction in villus shortening at 40 mg/ml; both p<0.01). In volunteers, indomethacin caused a threefold increase in gut permeability in the control arm; lactulose:rhamnose ratios were (mean (standard error of mean)) 0.35 (0.035) before indomethacin treatment and 0.88 (0.11) after 5 days of indomethacin treatment (p<0.01), whereas no significant increase in permeability was seen when ZnC was coadministered.
ZnC, at concentrations likely to be found in the gut lumen, stabilises gut mucosa. Further studies are warranted.
肌肽锌（ZnC）是一种声称具有促进健康和胃肠道支持活性的健康食品。然而，这些说法背后的科学证据有限。
研究肌肽锌对各种肠道损伤和修复模型的影响，并进行一项临床试验。
体外研究使用人结肠（HT29）、大鼠肠上皮（RIE）和犬肾（MDCK）上皮细胞的促迁移（伤口单层）和增殖（[³H] - 胸腺嘧啶核苷掺入）试验。体内研究使用胃损伤大鼠模型（吲哚美辛/束缚）和小肠损伤小鼠模型（吲哚美辛）。健康志愿者（n = 10）进行了一项随机交叉试验，比较在吲哚美辛治疗（每天三次，每次50 mg）5天期间，同时服用肌肽锌（每天两次，每次37.5 mg）或安慰剂前后肠道通透性（乳果糖：鼠李糖比率）的变化。
肌肽锌以剂量依赖性方式刺激细胞迁移和增殖（使用HT29细胞在两种试验中，100 μmol/l时达到最大效应），使迁移和增殖增加约三倍（两者p<0.01）。口服肌肽锌可减轻胃损伤（5 mg/ml时降低75%）和小肠损伤（40 mg/ml时绒毛缩短减少50%；两者p<0.01）。在志愿者中，吲哚美辛使对照组的肠道通透性增加了两倍；吲哚美辛治疗前乳果糖：鼠李糖比率为（平均值（平均标准误差））0.35（0.035），吲哚美辛治疗5天后为0.88（0.11）（p<0.01），而同时服用肌肽锌时未观察到通透性有显著增加。
在肠腔内可能存在的浓度下，肌肽锌可稳定肠道黏膜。有必要进行进一步研究。
